MedTrace Logo

CeraVe Diabetes Mellitus

NCT04724967 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 528

Last updated 2022-09-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of the CeraVe Diabetic Skin Line for the improvement of skin condition in patients with diabetes mellitus.

Conditions

  • Diabetes Complications

Interventions

DRUG

CeraVe Hydrating Cleanser

topical cleanser applied twice a day for 28 days

DRUG

CeraVe Moisturizing Cream

topical cream applied twice a day for 28 days

Sponsors & Collaborators

  • CeraVe

    collaborator INDUSTRY

  • University of Miami

    lead OTHER

Principal Investigators

  • Robert Kirsner, MD/PhD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-12
Primary Completion
2021-08-10
Completion
2021-08-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04724967 on ClinicalTrials.gov